Tharimmune, Inc. (CNTN) Stock

Tharimmune, Inc. (CNTN) is a Healthcare stock trading at $2.19 (as of 2026-08-21), with a market capitalization of $174.50M. Figures are sourced from first-party U.S. SEC EDGAR filings and market data.

Tharimmune, Inc. is a clinical-stage biotechnology company developing a portfolio of therapeutic candidates for inflammation and immunology. It also develops TH104, which is known to suppress chronic, debilitating pruritus or uncontrollable itching in PBC, a rare and orphan liver disease with no known cure. The company was founded on March 28, 2017 and is headquartered in Bridgewater, NJ.

Understand Tharimmune, Inc.: how it makes money

Tharimmune develops a portfolio of therapeutic candidates for inflammation, immunology and PBC-related itching, and its clinical-stage model depends on advancing those candidates toward future product revenue.

Tharimmune has a development-stage drug model, with costs incurred before any established product revenue.

Business quality (Unprofitable): The company is unprofitable, with operating margin -80%, and remains a clinical-stage biotech, so its investment case depends on development progress.

Bull case

  • Unmet need supports upside: TH104 is intended to suppress chronic, debilitating itching in PBC, a rare orphan liver disease with no known cure. If development succeeds, that stated unmet need could support adoption of a successful therapy.
  • Multiple candidates broaden optionality: The company is developing a portfolio across inflammation and immunology, alongside TH104. Progress across the portfolio could create multiple paths to value.

Bear case

  • Current losses constrain flexibility: The operating margin is -80%, showing that current operations are loss-making. Without evidence of established product revenue in the provided facts, sustained development could pressure financial flexibility.
Valuation — source: SEC EDGAR (first-party)
Price$2.19
Market Cap$174.50M
Price / Book0.38
Valuation vs Sector & Industry
Sector P/E (Healthcare)21.7
Industry P/E (Pharmaceutical Products)17.0
Smart-Money Activity — SEC Form 4 / 13F / Congressional disclosures
Top Institutional HolderARK Investment Management LLC ($12.08M)
Institutional Holders Tracked10
Company
SectorHealthcare
IndustryPharmaceutical Products
CEOMark Wendland
Employees2
CountryUS
IPO Date2024-03-28

Related Companies (Business model: Biotech (Clinical / Commercial-Stage); 8 closest by market cap; US-domiciled)

  • Oramed Pharmaceuticals Inc. (ORMP)
  • Korro Bio, Inc. (KRRO)
  • Nkarta, Inc. (NKTX)
  • Cue Biopharma, Inc. (CUE)
  • Lifecore Biomedical, Inc. (LFCR)
  • Indaptus Therapeutics, Inc. (INDP)
  • OnKure Therapeutics, Inc. (OKUR)
  • NRx Pharmaceuticals, Inc. (NRXP)
CNTN earnings history · CNTN institutional & insider holders · CNTN KPIs & operating metrics · CNTN financials · CNTN investor presentations & press releases · CNTN SEC filings · CNTN peers · Congress trades · Insider trades · Short interest · Stock screener

Data as of 2026-08-21.

Figures sourced from U.S. Securities and Exchange Commission (SEC EDGAR) filings and market data. Not personalized investment advice.